Medicine
Iopidine 1% 10 mg/mL eye drops
Iopidine 1% 10 mg/mL eye drops is a prescription medicine containing Apraclonidine for ophthalmic use, marketed by Harrow Eye, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 2°C to 25°C (36°F-77°F). Protect from light.
Key facts
- Active ingredient (INN)
- Apraclonidine
- Brand
- Iopidine 1%
- Strength
- 10 mg/mL
- Dosage form
- Eye drops
- Route
- Ophthalmic
- Packs
- 12 pouches, 5 pouches
- Marketing authorisation holder
- Harrow Eye
- Manufacturer
- Harrow Eye
- Origin register
- US FDA, United States
- Storage
- Store at 2°C to 25°C (36°F-77°F). Protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- S01EA03 Apraclonidine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 August 2023
- Identifiers
- RxCUI 211020, 308346DailyMed set ID 00f18845-ccde-8678-e063-6294a90a3374NDC 82667-200Application NDA019779
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 12 pouch in 1 carton / 2 vial, single-dose in 1 pouch / .1 mL in 1 vial, single-dose | 82667-200-01 | Harrow Eye | 1 August 2023 |
| 5 pouch in 1 carton / 5 vial, single-dose in 1 pouch / .1 mL in 1 vial, single-dose | 82667-200-05 | Harrow Eye | 1 May 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 31 December 1987 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Apraclonidine
Clinical summary
Apraclonidine is an alpha-adrenergic agonist indicated to control or prevent post-surgical elevations in IOP that occur in patients after argon laser trabeculoplasty, argon laser iridotomy or Nd:YAG posterior capsulotomy. MedsAcross supplies Apraclonidine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ApraclonidineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- IOPIDINE 1% prescribing information (Harrow Eye) · U.S. National Library of Medicine, DailyMed
Need Iopidine 1% 10 mg/mL eye drops for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.